- Resource
- Source: Campus Sanofi
- 1 Sept 2025
Dupixent (dupilumab) Resources
.png)
Expert Presentations
IL-4 in Type 2 Inflammation – Dr Alan Irvine
Watch Dr Irvine discuss the role of IL-4 in AD.
Video Playtime: 1min 46secs
RELIEVE-AD Results, long-term (3 years) treatment with DUPIXENT - Dr Stephan Weidinger
Watch Dr Weidinger present 3-year results from RELIEVE-AD Data.
Video Playtime: 1min 37secs
Needle Phobia – Dr Tim Clayton
Watch Dr Clayton discuss needle phobia in adolescents and children with atopic dermatitis.
Video Playtime: 4mins 14secs
Dupixent in patients as young as 6 months old with severe AD – expert panel discussions
Watch a panel of experts discuss the practicalities of using DUPIXENT in children aged <12 years through real-world case studies.
Video Playtime: 48mins 05secs
Patient Case Studies
DUPIXENT use in a 3-year old patient – Dr. Gabriela Petrof
Watch Dr. Gabriela Petrof present a case study of the use of DUPIXENT in a 3-year old patient with severe atopic dermatitis.
Video Playtime: 7mins 07secs
DUPIXENT use in a child patient with severe AD – Dr. Inge Kreuzer-Genis & Emily King
Watch Dr. Inge Kreuzer-Genis and Emily King present a clinical case study of the use of DUPIXENT in an 8-year old patient with severe atopic dermatitis.
Video Playtime: 13mins 52secs
Conjunctivitis Management
Conjunctivitis Management - Mr Scott Robbie
Watch Mr Scott Robbie discuss management of conjunctivitis in AD patients.
Video Playtime: 1min 45secs
Patient Guides
Please click below for available patient guides for patients prescribed with Dupixent:
Atopic Dermatitis Control Test (ADCT)
Atopic dermatitis, a type of eczema, may be affecting your patient’s life in more ways than you know.
The ADCT gives a measure of how controlled your patient’s eczema is. Use these 6 concise questions to evaluate all dimensions of atopic dermatitis control.
Development of ADCT involved literature review as well as interviews with patients and physicians, and was funded by Sanofi and Regeneron.
Try the ADCTMAT-XU-2304411 (v4.0) Date of Preparation: September 2025